News and Research
Immune System
Protein Helps Immune System Mount 'Instant Strike' Against
Deadly Flu Viruses
2-20-2004
Researchers at the University of Rochester have identified
a protein in the immune system that appears to play a crucial
role in protecting against deadly forms of influenza, and
may be particularly important in protecting against emerging
flu viruses like the avian flu. The researchers believe
that a vaccine made with a live but weakened strain of flu
virus – such as the inhaled flu vaccine introduced
last year – may activate this part of the immune system
and offer the best defense against avian flu.
In
a paper being published in the February 20 issue of Immunity,
the researchers report that a protein called VLA-1 enables
the immune system to develop "peripheral immunity"
by anchoring millions of virus-killing cells to tissues
along the airways and lungs, where flu enters the body.
The protein holds the cells in place and helps them survive
there for long periods – sometimes years – where
they stand ready to mount an immediate attack on the flu
virus.
In
a series of experiments, mice whose T cells were able to
make the protein were able to develop peripheral immunity,
and 90 percent of them survived after being infected with
a potentially deadly strain of flu. Mice with T-cells engineered
to lack the protein failed to develop peripheral immunity,
and only 60 percent of them survived after being infected
with the same flu virus.
|
|
The findings demonstrate that when confronted by a
potentially deadly flu strain, an effective first strike by T cells
in the lungs can mean the difference between life and death. To immunologist
David Topham, Ph.D., assistant professor of Microbiology and Immunology
at the University of Rochester and lead author of the study, the findings
reveal something else: a shortcoming in the world's most widely administered
flu vaccines. Those vaccines, made with fragments of "killed"
viruses, help the immune system make antibodies against the flu virus
but do not induce peripheral immunity.
The trouble with antibodies, says Topham, arises when
a flu virus changes, either by mutating or by swapping genes with
another virus – a scenario that experts fear would lead to a
pandemic of avian flu. When a virus changes, antibodies often have
difficulty recognizing the new virus and mobilizing the immune system
to attack. And even if they do, it takes two to three days for antibodies
to stimulate the production of T cells, and for those cells to begin
attacking the virus. Unlike antibodies, T cells are much more effective
at recognizing viruses that have changed, and they can attack instantly.
"In a lethal form of flu, like avian flu has
the potential to be, you may not have three days. A lethal infection
can gain such a foothold in that time that it can become very difficult
or impossible for the immune system to overcome it," said Topham.
Topham believes that to protect people against an
outbreak of avian flu, vaccine developers should switch to a vaccine
made with a live but weakened flu virus. Such vaccines are thought
to more closely mimic a natural encounter with the flu virus and are
more likely to induce peripheral immunity, which might deliver an
instant strike against the virus as the infection begins.
"When confronted by a deadly flu virus, the ability
to attack it instantly, as soon as the virus hits the lungs, might
mean the difference between life and death," said Topham. "Our
goal should be to design a vaccine that helps the immune system produce
peripheral immunity. A vaccine made from live virus offers the best
chance of accomplishing this."
The research was funded by the National Institutes
of Health, and conducted at the David H. Smith Center for Vaccine
Biology, part of the Aab Institute of Biomedical Sciences at the University
of Rochester Medical Center.
This story has been adapted from a news release issued
by University Of Rochester Medical Center, www.urmc.rochester.edu.
Next - Back
to Immune System Support